Design in nonlinear mixed effects models: Optimization using the Fedorov-Wynn algorithm and power of the Wald test for binary covariates

Statistics in Medicine

Volumn 26, Issue 28, 2007, Pages 5162-5179

  Retout, Sylvie ^a,b,c   Comets, Emmanuelle ^a,b,c   Samson, Adeline ^a,b,c   Mentré, France ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

Fisher information matrix; HIV; Nonlinear mixed effects models; Population design; Power; Wald test

Indexed keywords

ANTIRETROVIRUS AGENT;

ALGORITHM; ARTICLE; BIOSTATISTICS; CLINICAL RESEARCH; COMPUTER PROGRAM; CONTROLLED STUDY; EXPERIMENTAL MODEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; POPULATION RESEARCH; PROCESS OPTIMIZATION; SIMULATION; STATISTICAL MODEL; TREATMENT RESPONSE; VIRUS LOAD;

ALGORITHMS; ANTI-RETROVIRAL AGENTS; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MODELS, STATISTICAL; NONLINEAR DYNAMICS; OUTCOME ASSESSMENT (HEALTH CARE); RESEARCH DESIGN; STOCHASTIC PROCESSES; VIRAL LOAD;

EID: 36349024782     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2910     Document Type: Article

References (38)

1. Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Computers and Biomedical Research 1972; 5:411-459.
2. Wu H, Ding AA, De Gruttola V. Estimation of HIV dynamic parameters. Statistics in Medicine 1998; 17: 2463-2485.
3. Wu H, Ding AA. Population HIV-1 dynamics in vivo: applicable models and inferential tools for virological data from AIDS clinical trials. Biometrics 1999; 55:410-418.
4. Wu H. Statistical methods for HIV dynamic studies in AIDS clinical trials. Statistical Methods in Medical Research 2005; 14:171-192.
5. Ding AA, Wu H. Assessing antiviral potency of anti-HIV therapies in vivo by comparing viral decay rates in viral dynamic models. Biostatistics 2001; 2:13-29.
6. Wu H, Ding AA. Design of viral dynamics studies for efficiently assessing potency of anti-HIV therapies in AIDS clinical trials. Biometrical Journal 2002; 44:175-196.
7. Pillai GC, Mentré F, Steimer JL. Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science. Journal of Pharmacokinetics and Pharmacodynamics 2005; 32:161-183.
8. Lindstrom ML, Bates DM. Nonlinear mixed effects models for repeated measures data. Biometrics 1990; 46:673-687.
9. Beal SL, Sheiner LB. NONMEM Users Guides. University of California: San Francisco, 1992.
10. Pinheiro JC, Bates MD. Mixed-Effects Models in S and S-Plus. Springer: New York, 2000.
11. Pinheiro JC, Bates DM. Approximations to the log-likelihood function in the nonlinear mixed-effects model. Journal of Computational and Graphical Statistics 1995; 4:12-35.
12. Kuhn E, Lavielle M. Maximum likelihood estimation in nonlinear mixed effects models. Computational Statistics and Data Analysis 2005; 49:1020-1038.
13. http://www.math.u-psud.fr/~lavielle/monolix/
14. Girard P, Mentré F. A comparison of estimation methods in nonlinear mixed effects models using a blind analysis. Abstracts of the Annual Meeting of the Population Approach Group in Europe, 2005; 14 [www.pagemeeting.org/?abstract=834].
15. Al-Banna MK, Kelman AW, Whiting B. Experimental design and efficient parameter estimation in population pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 1990; 18:347-360.
16. Jonsson EN, Wade JR, Karlsson MO. Comparison of some practical sampling strategies for population pharmacokinetic studies. Journal of Pharmacokinetics and Biopharmaceutics 1996; 24:245-263.
17. Atkinson AC, Donev AN. Optimum Experimental Designs. Clarendon Press: Oxford, 1992.
18. Walter E, Pronzato L. Identification of Parametric Models from Experimental Data. Springer: New York, 1997.
19. Mentré F, Mallet A, Baccar D. Optimal design in random-effects regression models. Biometrika 1997; 84:429-442.
20. Retout S, Mentré F, Bruno R. Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics. Statistics in Medicine 2002; 21: 2623-2639.
21. Retout S, Mentré F. Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics. Journal of Biopharmaceutical Statistics 2003; 13:209-227.
22. Nedelman JR. On some 'disadvantages' of the population approach. American Association of Pharmaceutical Scientists 2005; 7:374-382.
23. Green B, Duffull SB. Prospective evaluation of a D-optimal designed population pharmacokinetic study. Journal of Pharmacokinetics and Pharmacodynamics 2003; 30:145-161.
24. Mentré F, Dubruc C, Thenot JP. Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children. Journal of Pharmacokinetics and Pharmacodynamics 2001; 28:299-319.
25. Retout S, Mentré F. Optimisation of individual and population designs using Splus. Journal of Pharmacokinetics and Pharmacodynamics 2003; 30:417-443.
26. Duffull S, Retout S, Mentré F. The use of simulated annealing for finding optimal population designs. Computer Methods and Programs in Biomedicine 2002; 69:25-35.
27. Fedorov VV. Theory of Optimal Experiments. Academic Press: New York, 1972.
28. Wynn HP. Results in the construction of D-optimum experimental designs. Journal of the Royal Statistical Society B 1972; 34:133-147.
29. Han C, Chaloner K. D- and c-optimal designs for exponential regression models used in viral dynamics, and other applications. Journal of Statistical Planning and Inference 2003; 115:585-601.
30. Kang D, Schwartz JB, Verotta D. A sample size computation method for non-linear mixed effects models with applications to pharmacokinetics models. Statistics in Medicine 2004; 23:2551-2566.
31. Kang D, Schwartz JB, Verotta D. Sample size computations for PK/PD population models. Journal of Pharmacokinetics and Pharmacodynamics 2005; 32:685-701.
32. Marschner IC. Design of HIV viral dynamics studies. Statistics in Medicine 1998; 17:2421-2434.
33. Samson A, Lavielle M, Mentré F. Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: application to HIV dynamics model. Computational Statistics and Data Analysis 2006; 51:1562-1574.
34. Louis TA. Finding the observed information matrix when using the EM algorithm. Journal of the Royal Statistical Society B 1982; 44:226-233.
35. Kiefer J, Wolfowitz J. Optimum designs in regression problems. Annals of Mathematical Statistics 1959; 30: 271-294.
36. Mallet A. A maximum likelihood estimation method for random coefficient regression models. Biometrika 1986; 73:645-656.
37. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282:103-107.
38. Wu H, Huang Y, Acosta EP et al. Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance. Journal of Acquired Immune Deficiency Syndromes 2005; 39:272-283.